Teva Pharmaceuticals USA, announced that the Food and Drug Administration (FDA) has approved an auto-injector device for AJOVY® (fremanezumab-vfrm) injection for migraines.
“The approval of the AJOVY auto-injector is another important step forward for Teva and the migraine community,” said Brendan O’Grady, Executive Vice President, North America Commercial, Teva. “AJOVY is the only FDA-approved anti-CGRP that offers the flexibility of quarterly (675 mg) or monthly (225 mg) dosing options, and we are pleased that patients and their healthcare providers will be able to decide if an auto-injector is the right administration option for their needs.”
